Key result
DOACs were associated with greater odds of DVT and PE compared with LMWH after bone sarcoma resection, with similar bleeding.
Why the study?
Postoperative VTE and wound complications are increased after sarcoma resection, but differences in VTE and bleeding complications between DOACs and LMWH following lower extremity resection remained unclear.
Do direct oral anticoagulants (DOACs) prevent deep venous thrombosis (DVT) and pulmonary embolism (PE) compared with low-molecular-weight heparin (LMWH) in patients undergoing resection of primary lower extremity bone or soft-tissue sarcoma?
Cohort (n=2,083)
Do direct oral anticoagulants (DOACs) prevent deep venous thrombosis (DVT) and pulmonary embolism (PE) compared with low-molecular-weight heparin (LMWH) in patients undergoing resection of primary lower extremity bone or soft-tissue sarcoma?
DOACs are associated with an increased risk of VTE compared to LMWH when used for prophylaxis after primary bone or soft tissue sarcoma resection.
Answers are grounded in this paper and cite their sources.
May support LMWH preference for VTE prophylaxis after sarcoma resection; leaves open randomized confirmation of DOAC inferiority.
INTRODUCTION: The incidence of postoperative venous thromboembolism (VTE) and wound complications is greater after sarcoma resection. We sought to identify differences in postoperative VTE and bleeding complications with direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) following resection of lower extremity primary bone or soft tissue sarcoma. METHODS: We retrospectively identified 2083 patients from the PearlDiver database who underwent resection of primary bone or soft tissue sarcoma of the lower extremity from January 2010 to October 2021 and prescribed LMWH or DOAC within 90-days postoperatively. The primary outcomes were comparison of postoperative incidence and odds of deep venous thrombosis (DVT), pulmonary embolism (PE), and bleeding complications within 90-days following resection. RESULTS: Patients prescribed DOACs had a greater odds of DVT (odds ratio [OR]: 1.60; 95% confidence interval [CI]: 1.06-2.41; p = 0.024) and PE (OR: 3.38; 95% CI: 1.96-5.86; p < 0.001) within 90-days following resection of bone sarcoma when compared with the LMWH cohort. Patients undergoing resection of soft tissue sarcomas also had greater odds DVT (OR: 1.65; 95% CI: 1.09-2.49; p = 0.016) and PE (OR: 2.62; 95% CI: 1.52-4.54; p < 0.001) in the DOAC cohort. There was no difference in the odds of bleeding complications. CONCLUSION: This study demonstrated an increased incidence and odds of VTE, but not bleeding complications, when using DOACs versus LMWH after primary bone or soft tissue sarcoma resection. LEVEL OF EVIDENCE: Level III.
No takes yet. Share an insight, caveat, or question.
LiBrizzi et al. (2023) conducted a cohort in primary lower extremity bone or soft-tissue sarcoma (n=2,083). Direct oral anticoagulants (DOACs) vs. Low-molecular-weight heparin (LMWH) was evaluated on deep venous thrombosis (DVT), pulmonary embolism (PE), and bleeding complications within 90-days following resection (OR 1.60, 95% CI 1.06-2.41, p=0.024). DOACs were associated with greater odds of DVT and PE compared with LMWH after bone sarcoma resection, with similar bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: